The purpose of the study was to determine the optimal ovarian stimulation protocol (OS) in oocyte donors (DO) by comparing the OS protocols using different forms of recombinant FSH in combination with either clomiphene citrate or gonadotropin releasing hormone antagonists. Study design. Prospective randomized crossover study. Materials and methods. The study included analysis of 44 OS cycles in 15 oocyte donors. The ovarian stimulation cycles were successively performed using two schemes. In the first variant (scheme 1), the OS started on the 2nd or 3rd day of the menstrual cycle with r-FSH with the addition of ant-GnRH ganirelix 0.25 mg daily from the day when the maximum follicle reached a diameter of 12—14 mm. In the second variant (scheme 2), the OS started on the 2nd or 3rd day of the menstrual cycle with a single dose of 100 µg or 150 µg of coryfolitropine-alpha administered subcutaneously. From the 8th-9th day of the OS, 100—150 IU of r-FSH was administered daily. Oral administration of 50—100 mg of clomiphene citrate per day began from the day of coryfolitropine-alpha administration and continued daily up to and including the day of the trigger introduction. Triptorelin acetate 0.2 mg was used as a trigger of the final maturation of the oocytes in all cases. The first comparison group consisted of 15 oocyte donors, in which OS was performed according to scheme 1 (n=18 OS), the second group consisted of the same 15 DOs that underwent OS according to scheme 2 (n=26 OS). Results. No significant difference was found between the two groups in terms of the stimulation duration, the number of M2 oocytes obtained, and the number of immature oocytes obtained. The average cost of OS in the second group was significantly (p=0,00002) lower than the average cost of OS in the first group. The level of satisfaction by the stimulation scheme in all donors in the second group was higher compared to the first group. The median number of visits to the clinic for 1 OS cycle in the group of the first stimulation scheme was 5 (5;5), while in the group of the second scheme — 4 (4;4) (p<0.05). Conclusion. The scheme of ovarian stimulation of oocyte donors with CC and coripollitropin-alpha is an efficient and safe alternative to the scheme with GnRH antagonists and daily forms of r-FSH, and can be defined as optimal. This scheme of OS allows reducing the number of injections and visits to the medical center.